520 related articles for article (PubMed ID: 26890785)
1. Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.
Grangeon L; Paquet C; Bombois S; Quillard-Muraine M; Martinaud O; Bourre B; Lefaucheur R; Nicolas G; Dumurgier J; Gerardin E; Jan M; Laplanche JL; Peoc'h K; Hugon J; Pasquier F; Maltête D; Hannequin D; Wallon D;
J Alzheimers Dis; 2016; 51(3):905-13. PubMed ID: 26890785
[TBL] [Abstract][Full Text] [Related]
2. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease.
Dorey A; Tholance Y; Vighetto A; Perret-Liaudet A; Lachman I; Krolak-Salmon P; Wagner U; Struyfs H; De Deyn PP; El-Moualij B; Zorzi W; Meyronet D; Streichenberger N; Engelborghs S; Kovacs GG; Quadrio I
JAMA Neurol; 2015 Mar; 72(3):267-75. PubMed ID: 25559883
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry.
Skillbäck T; Rosén C; Asztely F; Mattsson N; Blennow K; Zetterberg H
JAMA Neurol; 2014 Apr; 71(4):476-83. PubMed ID: 24566866
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.
Abu Rumeileh S; Lattanzio F; Stanzani Maserati M; Rizzi R; Capellari S; Parchi P
J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009
[TBL] [Abstract][Full Text] [Related]
5. Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer's Disease.
Hermann P; Haller P; Goebel S; Bunck T; Schmidt C; Wiltfang J; Zerr I
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215868
[TBL] [Abstract][Full Text] [Related]
6. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.
Riemenschneider M; Wagenpfeil S; Vanderstichele H; Otto M; Wiltfang J; Kretzschmar H; Vanmechelen E; Förstl H; Kurz A
Mol Psychiatry; 2003 Mar; 8(3):343-7. PubMed ID: 12660807
[TBL] [Abstract][Full Text] [Related]
7. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.
Brunnström H; Rawshani N; Zetterberg H; Blennow K; Minthon L; Passant U; Englund E
Alzheimers Dement; 2010 Mar; 6(2):104-9. PubMed ID: 20298970
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt-Jakob disease and autoimmune encephalitis.
Chang BK; Day GS; Graff-Radford J; McKeon A; Flanagan EP; Algeciras-Schimnich A; Mielke MM; Nguyen A; Jones DT; Toledano M; Kremers WK; Knopman DS; Petersen RC; Li W
Eur J Neurol; 2022 Oct; 29(10):2905-2912. PubMed ID: 35735602
[TBL] [Abstract][Full Text] [Related]
10. Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia.
Karch A; Llorens F; Schmitz M; Arora AS; Zafar S; Lange P; Schmidt C; Zerr I
J Alzheimers Dis; 2016 Oct; 54(4):1385-1393. PubMed ID: 27589519
[TBL] [Abstract][Full Text] [Related]
11. Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients.
Van Everbroeck B; Dobbeleir I; De Waele M; De Deyn P; Martin JJ; Cras P
J Neurol; 2004 Mar; 251(3):298-304. PubMed ID: 15015009
[TBL] [Abstract][Full Text] [Related]
12. Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease.
Sorensen KC; Simonsen AH; Holmetoft UB; Hasselbalch SG; Heegaard NH
J Alzheimers Dis; 2013; 37(2):379-87. PubMed ID: 23948879
[TBL] [Abstract][Full Text] [Related]
13. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease.
Buerger K; Otto M; Teipel SJ; Zinkowski R; Blennow K; DeBernardis J; Kerkman D; Schröder J; Schönknecht P; Cepek L; McCulloch C; Möller HJ; Wiltfang J; Kretzschmar H; Hampel H
Neurobiol Aging; 2006 Jan; 27(1):10-5. PubMed ID: 16298235
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
Shea YF; Ha J; Chu LW
Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
16. Follow-up investigations of tau protein and S-100B levels in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.
Cepek L; Steinacker P; Mollenhauer B; Wiese B; Ciesielczyk B; Bibl M; Wiltfang J; Zerr I; Schulz-Schaeffer W; Kretzschmar HA; Poser S; Otto M
Dement Geriatr Cogn Disord; 2005; 19(5-6):376-82. PubMed ID: 15802913
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Levels of 14-3-3 Gamma: What Does It Tell Us About Sporadic Creutzfeldt-Jakob Disease?
Humpel C; Benke T
Pharmacology; 2017; 100(5-6):243-245. PubMed ID: 28743115
[TBL] [Abstract][Full Text] [Related]
18. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
[TBL] [Abstract][Full Text] [Related]
19. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia.
Gloeckner SF; Meyne F; Wagner F; Heinemann U; Krasnianski A; Meissner B; Zerr I
J Alzheimers Dis; 2008 May; 14(1):17-25. PubMed ID: 18525124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
